The size of the Latin American in-vitro toxicology testing market is expected to worth USD 3672.35 Million by 2026 from USD 1875.83 Million in 2021, growing at a CAGR of 14.38% from 2021 to 2026.
In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is very essential in drug discovery as identifies the toxic effects of new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Availability of numerous animal welfare organizations that maintain the reduced utilization of animals for pre-clinical studies, rising investment in research & development to enhance the research in cell culture, increasing number of aging population, growing demand for healthy lifestyle are driving the growth of in-vitro toxicology testing market in Latin America. However, unawareness of advanced toxicology testing procedures and inadequate facilities (such as social & economic factors) for the advancements of new research technologies are restraining the growth of in-vitro toxicology testing market in Latin America.
This research report on the Latin America In-Vitro Toxicology Testing Market has been segmented and sub-segmented into the following categories:
By Product
By Type
By Toxicity Endpoints & Tests
By Technology
By Method
By Industry
By Country:
Notable companies in the Latin America In-Vitro Toxicology Testing Market are Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.) and Cyprotex (U.K.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Assays
5.1.3 Reagents & Labware
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 ADME (Absorption, Distribution, Metabolism, and Excretion)
5.2.3 Dose
5.2.4 Toxic Substance
5.3 Toxicity Endpoints & Tests
5.3.1 Introduction
5.3.2 Systemic Toxicity
5.3.3 Dermal Toxicity
5.3.4 Carcinogenicity
5.3.5 Ocular Toxicity
5.3.6 Skin Sensitization & Irritation
5.3.7 Genotoxicity
5.3.8 Neurotoxicity
5.3.9 Organ Toxicity
5.3.10 Other Toxicity Endpoints & Tests
5.4 Technology
5.4.1 Introduction
5.4.2 OMICS Technologies
5.4.3 Cell Culture Technology
5.4.4 High-Throughput Technologies
5.4.5 Molecular Imaging Technologies
5.5 Method
5.5.1 Introduction
5.5.2 In-Silico Methods
5.5.3 Biochemical Assays
5.5.4 Cellular Assays
5.5.5 Ex-Vivo Models
5.6 Industry
5.6.1 Introduction
5.6.2 Cosmetics and Household Products
5.6.3 Diagnostics
5.6.4 Pharmaceuticals
5.6.5 Food Industry
5.6.6 Chemicals
6. Geographical Analysis
6.1 Introduction
6.2 Brazil
6.3 Rest of Latin America
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Covance, Inc. (A subsidiary of LabCorp) (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Agilent Technologies, Inc. (U.S.)
8.3 Bio-Rad Laboratories, Inc. (U.S.)
8.4 Eurofins Scientific SE (Luxembourg)
8.5 General Electric Company (U.S.)
8.6 BioReliance, Inc. (U.S.)
8.7 Charles River Laboratories International, Inc. (U.S.)
8.8 Thermo Fisher Scientific, Inc. (U.S.)
8.9 Catalent (U.S.)
8.10 Cyprotex (U.K.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
